Reader TTS

ABSTRACT BACKGROUND: Organic anion-transporting polypeptides (OATPs) encoded by SLCO mediate the cellular uptake of many compounds, including androgens. _SLCO1B3_ and _SLCO2B1_ are

polymorphic, and single-nucleotide polymorphisms of those genes alter androgen transport efficiency. We aimed to investigate the association between genetic variations in SLCOs and the

progression to castration-resistant prostate cancer (CRPC). METHODS: We studied the progression to CRPC for the _SLCO1B3_ rs4149117 and _SLCO2B1_ rs12422149 genotypes in 87 prostate cancer

patients who received androgen deprivation therapy (ADT). Data were analyzed using the χ2 test, Kaplan–Meier survival analysis and Cox proportional hazard model. RESULTS: _SLCO3B1_ genotypes

were not significantly associated with the time to progression (TTP); however, patients carrying the active androgen transport _SLCO2B1_ genotype (GG allele) exhibited a median TTP that was

7 months shorter than that of patients with impaired androgen-transporting activity _SLCO2B1_ polymorphisms (GA/AA alleles) (10.0 vs 17.0 months, _P_=0.004). Active androgen transport

genotypes of _SLCO2B1_ (GG allele) occurred more frequently in African and Caucasian populations than in Japanese and Han Chinese populations (_P_<0.001). CONCLUSIONS: These data suggest

that _SLCO2B1_ rs12422149 variants could provide prognostic value for prostate cancer patients treated with ADT and influence ethnic differences in response to ADT. Active androgen import

may be one of the underlying mechanisms of resistance to ADT, and androgen-transporting systems could provide novel biomarkers and targets for CRPC treatment. Access through your institution

Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 4 print issues and

online access $259.00 per year only $64.75 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes

which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY

OTHERS THE ASSOCIATION BETWEEN MISSENSE POLYMORPHISMS IN _SRD5A2_ AND _HSD3B1_ AND TREATMENT FAILURE WITH ABIRATERONE FOR CASTRATION-RESISTANT PROSTATE CANCER Article 01 March 2021

EPIDEMIOLOGY AND GENOMICS OF PROSTATE CANCER IN ASIAN MEN Article 10 March 2021 CLINICAL CONSIDERATIONS FOR THE MANAGEMENT OF ANDROGEN INDIFFERENT PROSTATE CANCER Article 10 February 2021

REFERENCES * Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN _et al_. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate

cancer. _N Engl J Med_ 2004; 351: 1502–1512. Article  CAS  Google Scholar  * Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME _et al_. Docetaxel and estramustine compared

with mitoxantrone and prednisone for advanced refractory prostate cancer. _N Engl J Med_ 2004; 35: 1513–1520. Article  Google Scholar  * de Bono JS, Logothetis CJ, Molina A, Fizazi K, North

S, Chu L _et al_. Abiraterone and increased survival in metastatic prostate cancer. _N Engl J Med_ 2011; 364: 1995–2005. Article  CAS  Google Scholar  * de Bono JS, Oudard S, Ozguroglu M,

Hansen S, Machiels JP, Kocak I _et al_. TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel

treatment: a randomised open-label trial. _Lancet_ 2010; 376: 1147–1154. Article  CAS  Google Scholar  * Golshayan AR, Antonarakis ES . Enzalutamide: an evidence-based review of its use in

the treatment of prostate cancer. _Core Evid_ 2013; 8: 27–35. CAS  PubMed  PubMed Central  Google Scholar  * Hafeez S, Parker C . Radium-223 for the treatment of prostate cancer. _Expert

Opin Investig Drugs_ 2013; 22: 379–387. Article  CAS  Google Scholar  * Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF _et al_. Sipuleucel-T immunotherapy for

castration-resistant prostate cancer. _N Engl J Med_ 2010; 363: 411–422. CAS  PubMed  Google Scholar  * Attar RM, Takimoto CH, Gottardis MM . Castration-resistant prostate cancer: locking up

the molecular escape routes. _Clin Cancer Res_ 2009; 15: 3251–3255. Article  CAS  Google Scholar  * Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R _et al_. Molecular determinants

of resistance to antiandrogen therapy. _Nat Med_ 2004; 10: 33–39. Article  Google Scholar  * Fujimoto N, Miyamoto H, Mizokami A, Harada S, Nomura M, Ueta Y _et al_. Prostate cancer cells

increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells. _Cancer

Invest_ 2007; 25: 32–37. Article  CAS  Google Scholar  * Foley R, Marignol L, Keane JP, Lynch TH, Hollywood D . Androgen hypersensitivity in prostate cancer: molecular perspectives on

androgen deprivation therapy strategies. _Prostate_ 2011; 71: 550–557. Article  CAS  Google Scholar  * König J, Seithel A, Gradhand U, Fromm MF . Pharmacogenomics of human OATP transporters.

_Naunyn Schmiedebergs Arch Pharmacol_ 2006; 372: 432–443. Article  Google Scholar  * Hamada A, Sissung T, Price DK, Danesi R, Chau CH, Sharifi N _et al_. Effect of SLCO1B3 haplotype on

testosterone transport and clinical outcome in Caucasian patients with androgen-independent prostatic cancer. _Clin Cancer Res_ 2008; 14: 3312–3318. Article  CAS  Google Scholar  * Yang M,

Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T _et al_. _SLCO2B1_ and _SLCO1B3_ may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.

_J Clin Oncol_ 2011; 29: 2565–2573. Article  CAS  Google Scholar  * Pressler H, Sissung TM, Venzon D, Price DK, Figg WD . Expression of OATP family members in hormone-related cancers:

potential markers of progression. _PLoS One_ 2011; 6: e20372. Article  CAS  Google Scholar  * Wright JL, Kwon EM, Ostrander EA, Montgomery RB, Lin DW, Vessella R _et al_. Expression of SLCO

transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes. _Cancer Epidemiol Biomarkers Prev_ 2011; 20:

619–627. Article  CAS  Google Scholar  * Sharifi N, Hamada A, Sissung T, Danesi R, Venzon D, Baum C _et al_. A polymorphism in a transporter of testosterone is a determinant of androgen

independence in prostate cancer. _BJU Int_ 2008; 102: 617–621. Article  CAS  Google Scholar  * Fukagai T, Namiki TS, Carlile RG, Yoshida H, Namiki M . Comparison of the clinical outcome

after hormonal therapy for prostate cancer between Japanese and Caucasian men. _BJU Int_ 2006; 97: 1190–1193. Article  CAS  Google Scholar  * Holmes L Jr, Chan W, Jiang Z, Ward D, Essien EJ,

Du XL . Impact of androgen deprivation therapy on racial/ethnic disparities in the survival of older men treated for locoregional prostate cancer. _Cancer Control_ 2009; 16: 176–185.

Article  Google Scholar  * Tsujimoto M, Hirata S, Dan Y, Ohtani H, Sawada Y . Polymorphisms and linkage disequilibrium of the OATP8 (OATP1B3) gene in Japanese subjects. _Drug Metab

Pharmacokinet_ 2006; 21: 165–169. Article  Google Scholar  * Smith NF, Marsh S, Scott-Horton TJ, Hamada A, Mielke S, Mross K _et al_. Variants in the SLCO1B3 gene: interethnic distribution

and association with paclitaxel pharmacokinetics. _Clin Pharmacol Ther_ 2007; 81: 76–82. Article  CAS  Google Scholar  * Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue T _et al_.

Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. _Eur J Clin Pharmacol_ 2007; 63: 1161–1169.

Article  CAS  Google Scholar  * dbSNP http://www.ncbi.nlm.nih.gov/snp?term. * Laitinen A, Niemi M . Frequencies of single-nucleotide polymorphisms of SLCO1A2, SLCO1B3 and SLCO2B1 genes in a

Finnish population. _Basic Clin Pharmacol Toxicol_ 2011; 108: 9–13. Article  CAS  Google Scholar  * Taguchi M, Ichida F, Hirono K, Miyawaki T, Yoshimura N, Nakamura T _et al_.

Pharmacokinetics of bosentan in routinely treated Japanese pediatric patients with pulmonary arterial hypertension. _Drug Metab Pharmacokinet_ 2011; 26: 280–287. Article  CAS  Google Scholar

  * Inatomi H, Katoh T, Kawamoto T, Matsumoto T . NAT2 gene polymorphism as a possible marker for susceptibility to bladder cancer in Japanese. _Int J Urol_ 1999; 6: 446–454. Article  CAS 

Google Scholar  * Ikuyama T, Hamasaki T, Inatomi H, Katoh T, Muratani T, Matsumoto T . Association of vitamin D receptor gene polymorphism with renal cell carcinoma in Japanese. _Endocr J_

2002; 49: 433–438. Article  CAS  Google Scholar  * Hamasaki T, Inatomi H, Katoh T, Aono H, Ikuyama T, Muratani T _et al_. N-acetyltransferase-2 gene polymorphism as a possible biomarker for

prostate cancer in Japanese men. _Int J Urol_ 2003; 10: 167–173. Article  CAS  Google Scholar  * Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V _et al_. EAU guidelines on

prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. _Eur Urol_ 2011; 59: 572–583. Article  Google Scholar  * Cooperberg MR, Hinotsu S,

Namiki M, Ito K, Broering J, Carroll PR _et al_. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. _J Clin Oncol_ 2009; 27: 4306–4313. Article 

Google Scholar  * Scher HI, Sawyers CL . Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. _J Clin Oncol_ 2005;

23: 8253–8261. Article  CAS  Google Scholar  * Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ . Splicing of a novel androgen receptor resistance. _Cancer Res_ 2008; 68: 5469–5477.

Article  CAS  Google Scholar  * Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H _et al_. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and

promotes androgen depletion-resistant growth. _Cancer Res_ 2009; 69: 2305–2313. Article  CAS  Google Scholar  * Steinkamp MP, O'Mahony OA, Brogley M, Rehman H, Lapensee EW, Dhanasekaran

S _et al_. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. _Cancer Res_ 2009; 69: 4434–4442. Article  CAS  Google Scholar  *

Shiota M, Yokomizo A, Fujimoto N, Naito S . Androgen receptor cofactors in prostate cancer: potential therapeutic targets of castration-resistant prostate cancer. _Curr Cancer Drug Targets_

2011; 11: 870–881. Article  CAS  Google Scholar  * Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM _et al_. Increased expression of genes converting adrenal androgens to

testosterone in androgen-independent prostate cancer. _Cancer Res_ 2006; 66: 2815–2825. Article  CAS  Google Scholar  * Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano

CS _et al_. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. _Cancer Res_ 2008; 68: 4447–4454. Article  CAS  Google

Scholar  * Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA _et al_. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is

upregulated by treatment with CYP17A1 inhibitors. _Cancer Res_ 2011; 71: 6503–6513. Article  CAS  Google Scholar  Download references ACKNOWLEDGEMENTS We thank Ms Hisami Aono for her

technical assistance in genomic DNA extraction, PCR and DNA sequencing. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Urology, School of Medicine, University of Occupational

and Environmental Health, Kitakyushu, Japan N Fujimoto, H T T Bui, T Sho & T Matsumoto * Department of Public Health, School of Medicine, University of Occupational and Environmental

Health, Kitakyushu, Japan T Kubo * Department of Urology, Munakata Suikoukai General Hospital, Fukutsu, Japan H Inatomi * Department of Urology, Graduate School of Medical Sciences, Kyushu

University, Fukuoka, Japan M Shiota Authors * N Fujimoto View author publications You can also search for this author inPubMed Google Scholar * T Kubo View author publications You can also

search for this author inPubMed Google Scholar * H Inatomi View author publications You can also search for this author inPubMed Google Scholar * H T T Bui View author publications You can

also search for this author inPubMed Google Scholar * M Shiota View author publications You can also search for this author inPubMed Google Scholar * T Sho View author publications You can

also search for this author inPubMed Google Scholar * T Matsumoto View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to

N Fujimoto. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no conflict of interest. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE

Fujimoto, N., Kubo, T., Inatomi, H. _et al._ Polymorphisms of the androgen transporting gene _SLCO2B1_ may influence the castration resistance of prostate cancer and the racial differences

in response to androgen deprivation. _Prostate Cancer Prostatic Dis_ 16, 336–340 (2013). https://doi.org/10.1038/pcan.2013.23 Download citation * Received: 26 April 2013 * Revised: 01 June

2013 * Accepted: 26 June 2013 * Published: 30 July 2013 * Issue Date: December 2013 * DOI: https://doi.org/10.1038/pcan.2013.23 SHARE THIS ARTICLE Anyone you share the following link with

will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt

content-sharing initiative KEYWORDS * androgen transportation * castration resistance * _SLCO_ * polymorphism